381 related articles for article (PubMed ID: 31475117)
1. Liquid Biopsy in Oligometastatic Prostate Cancer-A Biologist's Point of View.
Stelcer E; Konkol M; Głȩboka A; Suchorska WM
Front Oncol; 2019; 9():775. PubMed ID: 31475117
[TBL] [Abstract][Full Text] [Related]
2. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
3. Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review.
Corrao G; Zaffaroni M; Bergamaschi L; Augugliaro M; Volpe S; Pepa M; Bonizzi G; Pece S; Amodio N; Mistretta FA; Luzzago S; Musi G; Alessi S; La Fauci FM; Tordonato C; Tosoni D; Cattani F; Gandini S; Petralia G; Pravettoni G; De Cobelli O; Viale G; Orecchia R; Marvaso G; Jereczek-Fossa BA
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34208918
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions.
Kucera R; Pecen L; Topolcan O; Dahal AR; Costigliola V; Giordano FA; Golubnitschaja O
EPMA J; 2020 Sep; 11(3):399-418. PubMed ID: 32843909
[TBL] [Abstract][Full Text] [Related]
5. Progress in Oligometastatic Prostate Cancer: Emerging Imaging Innovations and Therapeutic Approaches.
Oka R; Utsumi T; Noro T; Suzuki Y; Iijima S; Sugizaki Y; Somoto T; Kato S; Endo T; Kamiya N; Suzuki H
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339259
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
[TBL] [Abstract][Full Text] [Related]
7. The role of genetic markers in the management of prostate cancer.
Choudhury AD; Eeles R; Freedland SJ; Isaacs WB; Pomerantz MM; Schalken JA; Tammela TL; Visakorpi T
Eur Urol; 2012 Oct; 62(4):577-87. PubMed ID: 22695242
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
10. Oligometastatic Prostate Cancer.
Navrátil J; Poprach A; Lakomý R; Kocák I; Vašina J; Krupa P; Vyzula R
Klin Onkol; 2019; 32(2):97-100. PubMed ID: 30995848
[TBL] [Abstract][Full Text] [Related]
11. The current role of precision surgery in oligometastatic prostate cancer.
von Deimling M; Rajwa P; Tilki D; Heidenreich A; Pallauf M; Bianchi A; Yanagisawa T; Kawada T; Karakiewicz PI; Gontero P; Pradere B; Ploussard G; Rink M; Shariat SF
ESMO Open; 2022 Dec; 7(6):100597. PubMed ID: 36208497
[TBL] [Abstract][Full Text] [Related]
12. The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review.
Berzenji L; Debaenst S; Hendriks JMH; Yogeswaran SK; Lauwers P; Van Schil PE
Transl Lung Cancer Res; 2021 Jul; 10(7):3409-3419. PubMed ID: 34430376
[TBL] [Abstract][Full Text] [Related]
13. [
Sollini M; Bartoli F; Cavinato L; Ieva F; Ragni A; Marciano A; Zanca R; Galli L; Paiar F; Pasqualetti F; Erba PA
EJNMMI Res; 2021 Nov; 11(1):119. PubMed ID: 34837532
[TBL] [Abstract][Full Text] [Related]
14. Current advances of liquid biopsies in prostate cancer: Molecular biomarkers.
Alahdal M; Perera RA; Moschovas MC; Patel V; Perera RJ
Mol Ther Oncolytics; 2023 Sep; 30():27-38. PubMed ID: 37575217
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
16. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
Foffi G; Pastore A; Piazza F; Temussi PA
Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review.
Koo KC; Dasgupta P
Yonsei Med J; 2018 Jul; 59(5):567-579. PubMed ID: 29869454
[TBL] [Abstract][Full Text] [Related]
18. Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study.
Colosini A; Bernardi S; Foroni C; Pasinetti N; Guerini AE; Russo D; Bresciani R; Tomasi C; Magrini SM; Bardoscia L; Triggiani L
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740343
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
